Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma

CONCLUSIONS: The results demonstrated the long-term clinical benefit of tirabrutinib, with deep and durable response in a subset of patients and acceptable safety profile, while KPS and QoL scores were maintained.PMID:38690230 | PMC:PMC11059299 | DOI:10.1093/noajnl/vdae037

Source: Adv Data - May 1, 2024 Category: Epidemiology Authors: Hajime Yonezawa Yoshitaka Narita Motoo Nagane Kazuhiko Mishima Yasuhito Terui Yoshiki Arakawa Katsunori Asai Noriko Fukuhara Kazuhiko Sugiyama Naoki Shinojima Arata Aoi Ryo Nishikawa Source Type: research